Adoptive cell therapy with T cells reprogrammed to express chimeric antigen receptors (CAR-
T cells) has been highly successful in patients with hematological neoplasms. However, its …

Immunotherapy using chimeric antigen receptor (CAR)-engineered T-cells has achieved
unprecedented efficacy in selected hematological cancers. However, solid tumors such as …

Oncolytic viruses (OVs) promote the anti-tumor immune response as their replication, and
the subsequent lysis of tumor cells, triggers the activation of immune-sensing pathways …

The intricate interplay between the host and its microbiota has garnered increasing attention
in the past decade. Specifically, the emerging recognition of microorganisms within diverse …

Recombinant adenovirus (rAd) regimens, including replication-competent oncolytic
adenovirus (OAV) and replication-deficient adenovirus, have been identified as potential …

Abstract Interferon-α2b (IFN-α2b) is a highly active cytokine that belongs to the interferon-α
(IFN-α) family. IFN-α2b has beneficial antiviral, antitumour, antiparasitic and …

The application of chimeric antigen receptor (CAR) T cells in the management of
hematological malignancies has emerged as a noteworthy therapeutic breakthrough …

Oncolytic virus immunotherapy as a new tumor therapy has made remarkable achievements
in clinical practice. And metabolic reprogramming mediated by oncolytic virus has a …

The discovery of biomarkers, essential for successful drug development, is often hindered by
the limited availability of tissue samples, typically obtained through core needle biopsies …

On August 30, 2017, the US Food and Drug Administration (FDA) approved the use of
tisagenlecleucel (CTL-019; Kymriah®, Novartis, Basel, Switzerland), a CD19-directed …